Medicine
More
-
During a conference call on drugmaker Merck& Co.' s fourth-quarter results, executives discussed some of their experimental drugs in development, including suvorexant, a new type of insomnia medicine designed to limit the morning grogginess common with sleep aids. QUESTION: What prospects do you see for suvorexant if it's approved?
-
OLYMPIA, Wash.-- Abortion rights supporters and opponents packed a Washington state House hearing Thursday and debated a measure that would require insurers to pay for the procedure.
-
CHICAGO, Feb 1- After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year. "In my own personal view, I will consider this to be a landmark or a watershed," said Peggy Johnston, senior program officer at the Bill& Melinda Gates Foundation in Seattle.
-
THE SPARK: Spectrum said it revised a deal with its partner Allergan Inc., and will have the right to market the drug in the U.S., Europe, and other regions. Allergan will get a royalty payment on sales of the drug if it is approved in those markets.
-
OTTAWA, Jan 31- Canadian Finance Minister Jim Flaherty revealed on Thursday he is suffering from a serious skin disease and is taking steroids that make him appear bloated and red-faced, but that the problem is not preventing him from doing his job. Flaherty's health has been a source of speculation in Ottawa for months because of his changed appearance.
-
Their report in Thursday's New England Journal of Medicine says dogma and fallacies are detracting from real solutions to the nation's weight problems.
-
A new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer. David Penson of Vanderbilt University. The study appears in Thursday's New England Journal of Medicine.
-
OTTAWA, Jan 31- Canadian Finance Minister Jim Flaherty said that steroids he is taking for a rare skin disease has made him appear to be bloated, though the problem is not preventing him from doing his job, according to an interview published on Thursday. "Of late I've been getting too many questions about my appearance and the weight gain," he told the Globe and Mail.
-
Jan 30- AbbVie, the pharmaceuticals business spun off earlier this month by Abbott Laboratories, forecast 2013 earnings in line with Wall Street forecasts but slowing sales growth for its blockbuster Humira rheumatoid arthritis drug. AbbVie said it expects net earnings this year of $2.66 to $2.76 per share.
-
*AbbVie shares fall 0.8 pct. Jan 30- AbbVie, the pharmaceuticals business spun off earlier this month by Abbott Laboratories, forecast 2013 earnings in line with Wall Street forecasts but slowing sales growth for Humira, its blockbuster rheumatoid arthritis drug.
-
*Net loss of 35 cents/ share in fourth quarter. *Sees 2013 revenue $1.1 bln to $1.25 bln. Jan 29- Vertex Pharmaceuticals Inc on Tuesday reported a third straight quarterly loss as sales of its hepatitis C drug, Incivek, again fell sharply while research and development spending rose.
-
Shares of Keryx Biopharmaceuticals Inc. extended its gains Tuesday, a day after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.
-
ROME, Jan 29- Governments must not allow financial constraints caused by the current global economic crisis to stop them keeping their guard up against avian flu, the Food and Agriculture Organisation said on Tuesday.
-
NEW YORK-- Shares of Furiex Pharmaceuticals Inc. surged Monday after regulators approved three new diabetes drugs that Japanese drugmaker Takeda developed with help from Furiex. THE SPARK: On Friday, Takeda said the Food and Drug Administration approved the type 2 diabetes drug Nesina and the combination drugs Oseni and Kazano.
-
Shares of Oncolytics Biotech Inc. climbed Monday after the drug developer said its lead product Reolysin may have a broader use as a potential cancer treatment. The study delivered a compelling result by showing that the disease had either slowed or stabilized in about half the patients, Stifel Nicolaus analyst Brian Klein said.
-
NEW YORK-- Shares of Keryx Biopharmaceuticals Inc. soared Monday after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.
-
*Q4 adjusted earnings $1.40/ shr vs $1.46 view. BOSTON, Jan 28- Biogen Idec Inc said fourth-quarter net profit fell slightly due to a tax accounting error, but the company's shares rose more than 3 percent Monday on higher-than-expected drug sales and optimism over a new multiple sclerosis treatment.
-
WASHINGTON-- The Food and Drug Administration on Friday approved three new formulations of a Takeda Pharmaceuticals Co. Ltd. diabetes drug designed to help patients control their blood sugar. The FDA approved the drug in stand-alone form under the brand-name Nesina.
-
Jan 25- Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years. The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years.
-
"The X and Z trend was pretty hot and heavy eight or nine years ago- that's when we had names like Zoloft, Zyban and Zocor," said Vince Budd, senior vice president at brand consulting firm Addison Whitney's healthcare division, referring to popular drugs for depression and high cholesterol.